These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32169390)

  • 1. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.
    Beran J; Leroux-Roels G; Van Damme P; de Hoon J; Vandermeulen C; Al-Ibrahim M; Johnson C; Peterson J; Baker S; Seidl C; Dreisbach A; Karsten A; Corsaro B; Henry O; Lattanzi M; Bebia Z
    Vaccine; 2020 Apr; 38(16):3227-3234. PubMed ID: 32169390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
    Swamy GK; Metz TD; Edwards KM; Soper DE; Beigi RH; Campbell JD; Grassano L; Buffi G; Dreisbach A; Margarit I; Karsten A; Henry O; Lattanzi M; Bebia Z
    Vaccine; 2020 Oct; 38(44):6930-6940. PubMed ID: 32883555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
    Absalon J; Segall N; Block SL; Center KJ; Scully IL; Giardina PC; Peterson J; Watson WJ; Gruber WC; Jansen KU; Peng Y; Munson S; Pavliakova D; Scott DA; Anderson AS
    Lancet Infect Dis; 2021 Feb; 21(2):263-274. PubMed ID: 32891191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.
    Leroux-Roels G; Bebia Z; Maes C; Aerssens A; De Boever F; Grassano L; Buffi G; Margarit I; Karsten A; Cho S; Slobod K; Corsaro B; Henry O
    Clin Infect Dis; 2020 Jun; 70(12):2570-2579. PubMed ID: 31394574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
    Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
    Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.
    Heyderman RS; Madhi SA; French N; Cutland C; Ngwira B; Kayambo D; Mboizi R; Koen A; Jose L; Olugbosi M; Wittke F; Slobod K; Dull PM
    Lancet Infect Dis; 2016 May; 16(5):546-555. PubMed ID: 26869376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.
    Madhi SA; Koen A; Cutland CL; Jose L; Govender N; Wittke F; Olugbosi M; Sobanjo-Ter Meulen A; Baker S; Dull PM; Narasimhan V; Slobod K
    Clin Infect Dis; 2017 Nov; 65(11):1897-1904. PubMed ID: 29029127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants.
    Cohet C; Cheuvart B; Moerman L; Bi D; Caplanusi A; Kariyappa M; Lalwani S; Mitra M; Sapru A; Saha S; Varughese PV; Kompithra RZ; Gandhi S
    Hum Vaccin Immunother; 2021 Nov; 17(11):4646-4653. PubMed ID: 34428112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.
    Fabbrini M; Rigat F; Tuscano G; Chiarot E; Donders G; Devlieger R; Filippini S; Frigimelica E; Forte P; Wittke F; Halperin SA; Slobod K; Grandi G; Margarit I
    J Infect; 2018 May; 76(5):449-456. PubMed ID: 29374589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial.
    Donders GG; Halperin SA; Devlieger R; Baker S; Forte P; Wittke F; Slobod KS; Dull PM
    Obstet Gynecol; 2016 Feb; 127(2):213-21. PubMed ID: 26942345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study.
    Madhi SA; Izu A; Kwatra G; Jones S; Dangor Z; Wadula J; Moultrie A; Adam Y; Pu W; Henry O; Briner C; Cutland CL
    Clin Infect Dis; 2021 Sep; 73(5):e1170-e1180. PubMed ID: 33341870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
    Madhi SA; Anderson AS; Absalon J; Radley D; Simon R; Jongihlati B; Strehlau R; van Niekerk AM; Izu A; Naidoo N; Kwatra G; Ramsamy Y; Said M; Jones S; Jose L; Fairlie L; Barnabas SL; Newton R; Munson S; Jefferies Z; Pavliakova D; Silmon de Monerri NC; Gomme E; Perez JL; Scott DA; Gruber WC; Jansen KU
    N Engl J Med; 2023 Jul; 389(3):215-227. PubMed ID: 37467497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults.
    Kotloff KL; Fattom A; Basham L; Hawwari A; Harkonen S; Edelman R
    Vaccine; 1996 Apr; 14(5):446-50. PubMed ID: 8735558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.